Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Dowsett

Showing results (221-230 of 304) with videos related to

Pageof 31
Sort By:
British Journal of Cancer|April 14, 2010
EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapyA H Evans, S Pancholi, I Farmer, et al.
Journal of Clinical Pathology|March 3, 2004
Best Practice No 176: Updated recommendations for HER2 testing in the UKI O Ellis, J Bartlett, M Dowsett, et al.
Journal of Clinical Pathology|March 27, 2001
Recommendations for HER2 testing in the UKI O Ellis, M Dowsett, J Bartlett, et al.
British Journal of Cancer|January 1, 1997
A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of GuernseyH V Thomas, T J Key, D S Allen, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancerM Dowsett, D Smithers, J Moore, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2004
Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 statusJ M Dixon, J Jackson, M Hills, et al.
British Journal of Cancer|January 1, 1997
A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of GuernseyH V Thomas, T J Key, D S Allen, et al.
Oncology|January 1, 1997
A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancerU R Kleeberg, M Dowsett, R P Carrion, et al.
Cancer Research|August 1, 1995
Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancerS R Johnston, G Saccani-Jotti, I E Smith, et al.
Lancet (London, England)|January 31, 1981
Sex hormone binding globulin levels and prognosis in early breast cancerA L Harris, I E Smith, M Dowsett, et al.
Pageof 31

Showing results (221-230 of 304) with videos related to

Sort By:
Pageof 31
British Journal of Cancer|April 14, 2010
EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapyA H Evans, S Pancholi, I Farmer, et al.
Journal of Clinical Pathology|March 3, 2004
Best Practice No 176: Updated recommendations for HER2 testing in the UKI O Ellis, J Bartlett, M Dowsett, et al.
Journal of Clinical Pathology|March 27, 2001
Recommendations for HER2 testing in the UKI O Ellis, M Dowsett, J Bartlett, et al.
British Journal of Cancer|January 1, 1997
A prospective study of endogenous serum hormone concentrations and breast cancer risk in premenopausal women on the island of GuernseyH V Thomas, T J Key, D S Allen, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1994
Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancerM Dowsett, D Smithers, J Moore, et al.
European Journal of Cancer (Oxford, England : 1990)|December 2, 2004
Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptor-positive breast cancers, irrespective of the erbB2 statusJ M Dixon, J Jackson, M Hills, et al.
British Journal of Cancer|January 1, 1997
A prospective study of endogenous serum hormone concentrations and breast cancer risk in post-menopausal women on the island of GuernseyH V Thomas, T J Key, D S Allen, et al.
Oncology|January 1, 1997
A randomised comparison of oestrogen suppression with anastrozole and formestane in postmenopausal patients with advanced breast cancerU R Kleeberg, M Dowsett, R P Carrion, et al.
Cancer Research|August 1, 1995
Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancerS R Johnston, G Saccani-Jotti, I E Smith, et al.
Lancet (London, England)|January 31, 1981
Sex hormone binding globulin levels and prognosis in early breast cancerA L Harris, I E Smith, M Dowsett, et al.
Pageof 31